EANM’12 – CTE Session I
EANM/SNM/ESTRO Joint Session
October 28, 2012, 08:15 – 09:45
New Tracers for PET/CT in RT Planning
Moderators: B. King (Los Angeles), M. Federspiel (Copenhagen)
Upon completion of this session the attendee will have an understanding of:
- Identify PET biomarkers for tumour receptor imaging and discuss their impact on therapy planning.
- Outline PET biomarkers for up-regulation of metabolism, proliferation, and protein synthesis and discuss their impact on therapy.
- Identify the importance of hypoxia imaging in therapy and identify PET biomarkers that can be used to detect hypoxic tumors.
- Summarise, conceptually, regulations which are associated with this field.
- State the major challenges of PET radiopharaceutical production.
- Indicate the differences between spontaneous syngenic tumours and experimentally induced xenografted tumours in the evaluation of functional PET tracers.
- Illustrate the benefits and potential of large animal models for the evaluation and development of equipment for clinical use on human patients.
- State ethical and practical issues when performing PET and radiotherapy studies using large animal spontaneous cancer models.
This session is intended for radiographers and nuclear medicine technologists working with PET/CT radiotherapy planning. New tracers for metabolism, proliferation, and protein synthesis will be presented and their impact on therapy will be focused. The second talk is a practical approach on how a new tracer is produced, starting from obtaining the official governmental permission to the first few productions. The third presentation will demonstrate how dogs are utilized in combined PET and radiotherapy treatment planning for the evaluation of various new tracers and will also focus on ethical and practical issues when scanning animals in a hospital environment.
PET/CT and Radiotherapy, Metabolism, Proliferation, Protein Synthesis, Hypoxia, Animal Models